Assertio Therapeutics (NASDAQ: ASRT) reported Q1 EPS of ($0.14), $0.09 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $26.49 million versus the consensus estimate of $27.52 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.